
SRRK Stock Forecast & Price Target
SRRK Analyst Ratings
Bulls say
Scholar Rock Holding is a biopharmaceutical company focused on developing innovative treatments for rare neuromuscular diseases. With promising clinical-stage pipeline candidates such as apitegromab and SRK-439, and a strong focus on early engagement with payers, the company is well positioned for future success. Additionally, with a diverse portfolio and a recent regulatory de-risking event, the company's strong financials and commitment to expanding the addressable patient population make it a compelling investment opportunity.
Bears say
Scholar Rock Holding is a biopharmaceutical company with a clinical-stage pipeline and early-stage programs focused on therapies for rare neuromuscular diseases. While the company has seen recent successes with the FDA's formal acceptance of their BLA resubmission and progress on their commercial launch plans, there are still risks to consider. Apitegromab and SRK-439 may not show sufficient efficacy and gene therapies could also limit the company's addressable market. Additionally, the company's valuation, based on a sum-of-parts analysis, may not be favorable for investors.
This aggregate rating is based on analysts' research of Scholar Rock Holding Corp and is not a guaranteed prediction by Public.com or investment advice.
SRRK Analyst Forecast & Price Prediction
Start investing in SRRK
Order type
Buy in
Order amount
Est. shares
0 shares